# Observational Study of Afatinib 30 mg Daily

> **NCT04909073** · — · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 69 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Epidermal Growth Factor Receptor Mutation

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT04909073
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-25
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909073, "Observational Study of Afatinib 30 mg Daily". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04909073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*